Plasminogen activator inhibitor monoclonal antibodies, hybridomas,

Abstract

In a method of producing monoclonal antibodies against endothelial type plasminogen activator inhibitor and immunologically similar inhibitors myeloma cells are fused with antibody-producing cells obtained from mammals which have been immunized with said plasminogen activator inhibitor or with antibody-producing cells, which in vitro have been immunized with said plasminogen activator inhibitor and the hybridomas producing antibodies against the above mentioned inhibitor are selected. The antibody-producing cells are preferably spleen cells or lymph node cells, most preferably spleen cells, obtained from mice immunized with the above mentioned inhibitor. The monoclonal antibodies against endothelial type plasminogen activator inhibitor can be used for purification of plasminogen activator inhibitor, for removal of plasminogen activator inhibitor, from body fluids and other biological materials, for neutralization of the inhibitory activity of the plasminogen activator inhibitor and for detection, identification, immunostaining and quantification, e.g. by the ELISA technique, of plasminogen activator inhibitor in body fluids, normal or malignant cells and tissues, and other biological materials. Furthermore, as some of the monoclonal antibodies obtained bound complexes of urikinase type plasminogen activator with endothelial type inhibitor while others did not, the monoclonal antibodies obtained can be used for the quantification of free versus complex-bound inhibitor.